Cargando…

201 Clinical Efficacy and Mucosal/Systemic Antibody Response Changes After Sublingual Immunotherapy in Mite-Allergic Children: A Randomized Double-Blind, Placebo-Controlled Study in Brazil

BACKGROUND: This study aimed to evaluate the clinical efficacy and mucosal/systemic antibody response changes after sublingual immunotherapy (SLIT) using Dermatophagoides pteronyssinus (Dpt) allergens with or without bacterial extracts in mite-allergic Brazilian children. METHODS: One-hundred and 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Queirós, Meimei, Silva, Deise, Simanc, Isabella, Ynouec, Leandro, Araújoc, Núbia, Pereira, Fernando, Almeida, Karine, Mirandac, Juliana, Pena, Janethe, Taketomi, Ernesto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: World Allergy Organization Journal 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3512804/
http://dx.doi.org/10.1097/01.WOX.0000411958.56416.28
_version_ 1782251805826088960
author Queirós, Meimei
Silva, Deise
Simanc, Isabella
Ynouec, Leandro
Araújoc, Núbia
Pereira, Fernando
Almeida, Karine
Mirandac, Juliana
Pena, Janethe
Taketomi, Ernesto
author_facet Queirós, Meimei
Silva, Deise
Simanc, Isabella
Ynouec, Leandro
Araújoc, Núbia
Pereira, Fernando
Almeida, Karine
Mirandac, Juliana
Pena, Janethe
Taketomi, Ernesto
author_sort Queirós, Meimei
collection PubMed
description BACKGROUND: This study aimed to evaluate the clinical efficacy and mucosal/systemic antibody response changes after sublingual immunotherapy (SLIT) using Dermatophagoides pteronyssinus (Dpt) allergens with or without bacterial extracts in mite-allergic Brazilian children. METHODS: One-hundred and 2 patients presenting allergic rhinitis with or without asthma were selected for a randomized double-blind, placebo-controlled trial and distributed into 3 groups: DPT (Dpt allergen extract, n = 34), DPT + MRB (Dpt allergen plus mixed respiratory bacterial extracts, n = 36), and Placebo (n = 32). Clinical evaluation and immunological analyses were carried out before and after 12 and 18 months of treatment, including rhinitis/asthma symptom and medication scores, skin prick test (SPT) to Dpt extract, and measurements of Dpt-, Der p 1-, Der p 2-specific IgE, IgG4, and IgG1 in serum and -specific IgA in saliva and nasal lavage fluid. RESULTS: Clinical results showed a significant decline in rhinitis/asthma symptom scores in all groups, but medication use decreased only in active DPT group at 12 months. SPT results showed no significant changes and SLIT was generally safe, with no severe systemic reactions. SLIT using Dpt allergen alone induced increased serum IgG4 levels to Dpt, Der p 1 and Der p 2, and increased serum IgG1 and salivary IgA levels to Dpt and Der p 1. SLIT using DPT+MRB was able to decrease IgE levels, particularly to Der p 2, to increase salivary IgA levels to Der p 1, but had no changes on specific IgG4 and IgG1 levels. CONCLUSIONS: Therefore, SLIT seems to be effective in ameliorating clinical symptoms, but only active SLIT was able to modulate the mucosal and systemic antibody responses. These findings support the role of specific serum IgG4 and IgG1, in addition to salivary IgA, as protective or blocking antibodies as well as biomarkers of tolerance that may be useful for monitoring activation of tolerance-inducing mechanisms during allergen immunotherapy.
format Online
Article
Text
id pubmed-3512804
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher World Allergy Organization Journal
record_format MEDLINE/PubMed
spelling pubmed-35128042012-12-21 201 Clinical Efficacy and Mucosal/Systemic Antibody Response Changes After Sublingual Immunotherapy in Mite-Allergic Children: A Randomized Double-Blind, Placebo-Controlled Study in Brazil Queirós, Meimei Silva, Deise Simanc, Isabella Ynouec, Leandro Araújoc, Núbia Pereira, Fernando Almeida, Karine Mirandac, Juliana Pena, Janethe Taketomi, Ernesto World Allergy Organ J Abstracts of the XXII World Allergy Congress BACKGROUND: This study aimed to evaluate the clinical efficacy and mucosal/systemic antibody response changes after sublingual immunotherapy (SLIT) using Dermatophagoides pteronyssinus (Dpt) allergens with or without bacterial extracts in mite-allergic Brazilian children. METHODS: One-hundred and 2 patients presenting allergic rhinitis with or without asthma were selected for a randomized double-blind, placebo-controlled trial and distributed into 3 groups: DPT (Dpt allergen extract, n = 34), DPT + MRB (Dpt allergen plus mixed respiratory bacterial extracts, n = 36), and Placebo (n = 32). Clinical evaluation and immunological analyses were carried out before and after 12 and 18 months of treatment, including rhinitis/asthma symptom and medication scores, skin prick test (SPT) to Dpt extract, and measurements of Dpt-, Der p 1-, Der p 2-specific IgE, IgG4, and IgG1 in serum and -specific IgA in saliva and nasal lavage fluid. RESULTS: Clinical results showed a significant decline in rhinitis/asthma symptom scores in all groups, but medication use decreased only in active DPT group at 12 months. SPT results showed no significant changes and SLIT was generally safe, with no severe systemic reactions. SLIT using Dpt allergen alone induced increased serum IgG4 levels to Dpt, Der p 1 and Der p 2, and increased serum IgG1 and salivary IgA levels to Dpt and Der p 1. SLIT using DPT+MRB was able to decrease IgE levels, particularly to Der p 2, to increase salivary IgA levels to Der p 1, but had no changes on specific IgG4 and IgG1 levels. CONCLUSIONS: Therefore, SLIT seems to be effective in ameliorating clinical symptoms, but only active SLIT was able to modulate the mucosal and systemic antibody responses. These findings support the role of specific serum IgG4 and IgG1, in addition to salivary IgA, as protective or blocking antibodies as well as biomarkers of tolerance that may be useful for monitoring activation of tolerance-inducing mechanisms during allergen immunotherapy. World Allergy Organization Journal 2012-02-17 /pmc/articles/PMC3512804/ http://dx.doi.org/10.1097/01.WOX.0000411958.56416.28 Text en Copyright © 2012 by World Allergy Organization
spellingShingle Abstracts of the XXII World Allergy Congress
Queirós, Meimei
Silva, Deise
Simanc, Isabella
Ynouec, Leandro
Araújoc, Núbia
Pereira, Fernando
Almeida, Karine
Mirandac, Juliana
Pena, Janethe
Taketomi, Ernesto
201 Clinical Efficacy and Mucosal/Systemic Antibody Response Changes After Sublingual Immunotherapy in Mite-Allergic Children: A Randomized Double-Blind, Placebo-Controlled Study in Brazil
title 201 Clinical Efficacy and Mucosal/Systemic Antibody Response Changes After Sublingual Immunotherapy in Mite-Allergic Children: A Randomized Double-Blind, Placebo-Controlled Study in Brazil
title_full 201 Clinical Efficacy and Mucosal/Systemic Antibody Response Changes After Sublingual Immunotherapy in Mite-Allergic Children: A Randomized Double-Blind, Placebo-Controlled Study in Brazil
title_fullStr 201 Clinical Efficacy and Mucosal/Systemic Antibody Response Changes After Sublingual Immunotherapy in Mite-Allergic Children: A Randomized Double-Blind, Placebo-Controlled Study in Brazil
title_full_unstemmed 201 Clinical Efficacy and Mucosal/Systemic Antibody Response Changes After Sublingual Immunotherapy in Mite-Allergic Children: A Randomized Double-Blind, Placebo-Controlled Study in Brazil
title_short 201 Clinical Efficacy and Mucosal/Systemic Antibody Response Changes After Sublingual Immunotherapy in Mite-Allergic Children: A Randomized Double-Blind, Placebo-Controlled Study in Brazil
title_sort 201 clinical efficacy and mucosal/systemic antibody response changes after sublingual immunotherapy in mite-allergic children: a randomized double-blind, placebo-controlled study in brazil
topic Abstracts of the XXII World Allergy Congress
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3512804/
http://dx.doi.org/10.1097/01.WOX.0000411958.56416.28
work_keys_str_mv AT queirosmeimei 201clinicalefficacyandmucosalsystemicantibodyresponsechangesaftersublingualimmunotherapyinmiteallergicchildrenarandomizeddoubleblindplacebocontrolledstudyinbrazil
AT silvadeise 201clinicalefficacyandmucosalsystemicantibodyresponsechangesaftersublingualimmunotherapyinmiteallergicchildrenarandomizeddoubleblindplacebocontrolledstudyinbrazil
AT simancisabella 201clinicalefficacyandmucosalsystemicantibodyresponsechangesaftersublingualimmunotherapyinmiteallergicchildrenarandomizeddoubleblindplacebocontrolledstudyinbrazil
AT ynouecleandro 201clinicalefficacyandmucosalsystemicantibodyresponsechangesaftersublingualimmunotherapyinmiteallergicchildrenarandomizeddoubleblindplacebocontrolledstudyinbrazil
AT araujocnubia 201clinicalefficacyandmucosalsystemicantibodyresponsechangesaftersublingualimmunotherapyinmiteallergicchildrenarandomizeddoubleblindplacebocontrolledstudyinbrazil
AT pereirafernando 201clinicalefficacyandmucosalsystemicantibodyresponsechangesaftersublingualimmunotherapyinmiteallergicchildrenarandomizeddoubleblindplacebocontrolledstudyinbrazil
AT almeidakarine 201clinicalefficacyandmucosalsystemicantibodyresponsechangesaftersublingualimmunotherapyinmiteallergicchildrenarandomizeddoubleblindplacebocontrolledstudyinbrazil
AT mirandacjuliana 201clinicalefficacyandmucosalsystemicantibodyresponsechangesaftersublingualimmunotherapyinmiteallergicchildrenarandomizeddoubleblindplacebocontrolledstudyinbrazil
AT penajanethe 201clinicalefficacyandmucosalsystemicantibodyresponsechangesaftersublingualimmunotherapyinmiteallergicchildrenarandomizeddoubleblindplacebocontrolledstudyinbrazil
AT taketomiernesto 201clinicalefficacyandmucosalsystemicantibodyresponsechangesaftersublingualimmunotherapyinmiteallergicchildrenarandomizeddoubleblindplacebocontrolledstudyinbrazil